Drug regulatory paradigm and challenges for Medical devices in India
The medical device industry in India has made speedy growth in the last few years but lag behind as compared to developed nations like USA, UK, etc. The government has taken the right step by separating the medical devices from general medicines from regulation viewpoint. Medical devices in India are governed by national drug regulatory agency, CDSCO (Central Drug Standard Control Organization) for quality and manufacturing standards. The CDSCO regulations are given to maintain the quality in manufacturing, packing and distribution of medical products. Each developed country has their own regulatory approval procedure and renewal requirements. The Indian government also adopted strict rules and regulations with respect to medical device and framed the new Medical Device Rules-2017. The medical device industry is principally import driven market close up to 75% and export up to 38% only. The national medical device policy2015 is driven out to strengthen the market of medical device and to reduce the burden on import of medical device (1). Recently NPPA capped the prices of medical devices such as coronary stents and knee implants under the DPCO (Drug Price Control Order). NPPA is the organization of government of INDIA which was established, to regulate the prices of controlled bulk drugs and formulations and in some extent medical devices. The NPPA have a mixed impact on Indian population and market, a large number of Indian population have received major benefits with respect to their healthcare costs (2, 3), at the same time major device manufacturer such as Abbott Healthcare , Medtronic filed the application to NPPA to increase the ceiling prices of their latest generation medical devices. As a negative impact, the MNCs withdraw their latest innovated products, affecting the quality of medical services, medical tourism, no investment in research and development of medical device etc.
Recommendations to government include: spending more percentage of GDP on healthcare, prioritizing the most important medical devices and provide them at subsidize price to government organization. The government should have more focus on production/manufacturing of medical devices indigenously under “Make in India” scheme.
http://pharmaceuticals.gov.in/sites/default/files/Draft National Medical Device Policy - 2015.pdf
2. National Pharmaceutical Pricing Authority [Internet]. [cited 2018 Dec 06]. Available from: http://nppaindia.nic.in/
3. DPCO/NPPA | Department of Pharmaceuticals [Internet]. NPPA; 2015 Aug [cited 2018 Nov 30 ]. Available from:
4. WHO | Medical devices. WHO [Internet]. WHO; 2018 [cited 2018 Dec 02]; Available from:
5. Patel SJA. Current regulatory challenges and approaches in registering In- Vitro Diagnostics( IVD) in India. J basics Clin Pharm; 2017.
6. Annexure-1 LIST OF MEDICAL DEVICES AND IN VITRO DIAGNOSTICS ALONG WITH THEIR RISK CLASS AS PER THE PROVISIONS OF RULE 4 OF THE MEDICAL DEVICES RULES 2017 (A) List of Medical Devices under provisions of sub-rule (1) rule 4 of the medical devices rules 2017 [Internet]. CDSCO; 2017 Nov 01 [cited 2019 Mar 03]. Available from:
http://www.cdsco.nic.in/writereaddata/Classification wise list of MD and IVDs17.pdf
7. Sehgal Charu BA. Medical Devices Making in India-A Leap for Indian Healthcare [Internet]. 2016 [cited 2018 Dec 25 ]. Available from:
8. The medical device industry in India [Internet]. 2016 [cited 2019 Jan 12]. Available from:
9. B.H.Daniela VV. Opportunities in the Medical Equipment Market India I Make in India Business Support Programme; [Internet]. 2017 [cited 2019 Mar 03]. Available from:
10. Peter Dinesh. VIEW POINT INDIAN MEDICAL DEVICE INDUSTRY-CURRENT STATE & OPPORTUNITIES FOR GROWTH [Internet]. 2018 [cited 2019 Jan 28]. Available from:
11. Nadimpalli R, Balamuralidhara V, Teggina M, Pramod Kumar VR. Regulatory guidelines for medical devices in India: An overview. Asian J Pharm [Internet]. [cited 2019 Jan 18]. Available from:
12.Yewale C, Baradia D, Patil S, Bhatt P, Amrutiya J, Gandhi R, et al. Docetaxel loaded immunonanoparticles delivery in EGFR overexpressed breast carcinoma cells. Journal of Drug Delivery Science and Technology. 2018;45:334-45.
13. THE DRUGS AND COSMETICS ACT AND RULES 1945 [Internet]. 2005 [cited 2018 Dec 02]. Available from: http://www.cdsco.nic.in/writereaddata/drugs&cosmeticact.pdf
14. Brolin S, Zhang L, Hamp S. Global Regulatory Requirements for Medical Devices [Internet]. [cited 2019 Mar 3]. Available from:
15. The Indian Medical Device Industry Regulatory, Legal and Tax Overview [Internet]. 2019 [cited 2018 Dec 08]. Available from: www.nishithdesai.com
16.Sethi R, Popli H, Sethi S. Medical Devices Regulation in United States of America, European Union and India: A Comparative Study. Pharm Regul Aff Open Access [Internet]. 2017 Jan 24 [cited 2018 Dec 03]; 06(01):1–9. Available from:
17. GHTF. GHTF SG1 Principles of Medical Devices Classification - November 2012 [Internet]. 2012 [cited 2019 Mar 03]. Available from:
18.Vhora I, Patil S, Bhatt P, Misra A. Protein- and Peptide-drug conjugates: an emerging drug delivery technology. Advances in protein chemistry and structural biology. 2015; 98:1-55.
19. Eshwara R. 53rd meeting of the drug consultative committee [Internet]. [cited 2019 Mar 03]. Available from:
20. AdvaMed S. Medical Device Industry in India - The evolving landscape, opportunities and challenges [Internet]. 2017 [cited 2019 Mar 03]. Available from:
21. West Bengal Clinical Establishments Bill, 2017 | Lexplosion Solutions [Internet]. [cited 2019 Mar 03]. Available from: https://www.lexplosion.in/government-of-west-bengal-issues-the-west-bengal-clinical-establishments-registration-regulation-and-transparency-bill-2017/
22. Medical device manufacturers are facing a lot of challenges [Internet]. [cited 2019 Mar 03]. Available from:
23.Yadav Vibhu, Kumar Dushant MN. New Regulatory Paradigm for Medical Devices in India [Internet]. [cited 2019 Mar 03]. Available from:
file:///C:/Users/ASUS/Desktop/2017 Nov Regulatory Focus New regulatory paradigm India Yadav Kumar Mathewson.pdf
24. Swaminathan.J P. Current Regulatory Challenges and Approaches in Registering In-Vitro Diagnostics (IVD’s) in India. J Basic Clin Pharma [Internet]. 2017[cited 2019 Mar 01]. Available from:
file:///D:/Anshul/laptop/medical device/Current Regulatory Challenges and Approaches in Registering In-Vitro Diagnostics (IVD’s) in India.pdf
25.Vhora I, Patil S, Bhatt P, Gandhi R, Baradia D, Misra A. Receptor-targeted drug delivery: current perspective and challenges. Therapeutic delivery. 2014; 5(9):1007-24.
26. The karnataka private medical establishments (amendment) act; 2017.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The International Journal of Drug Regulatory affairs require a formal written transfer of copyright from the author(s) for each article published. We therefore ask you to complete and return this form, retaining a copy for your records. Your cooperation is essential and appreciated. Any delay will result in a delay in publication.
I/we have read and agree with the terms and conditions stated Page 2 of this agreement and I/we hereby confirm the transfer of all copyrights in and relating to the above-named manuscript, in all forms and media, now or hereafter known, to the International Journal of Drug Regulatory affairs, effective from the date stated below. I/we acknowledge that the IJDRA is relying on this agreement in publishing the above-named manuscript. However, this agreement will be null and void if the manuscript is not published in the IJDRA.
Download link for COPYRIGHT FORM